A Long-Term Follow-Up Study of Subjects Completing the AU-011-301(CoMpass) for Early Choroidal Melanoma

Part of paid clinical trials in Sacramento, California.

Sponsor
Aura Biosciences
Study ID
NCT07338968
Status
Enrolling By Invitation

Conditions

  • Choroidal Melanoma
  • Indeterminate Lesions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Observational — OTHER
    The intention is to collect data for an additional \~5 years (Post AU-011-301 participation)

Study Details

AU-011-403 is a multicenter long-term follow-up safety and efficacy study of subjects with early CM who previously participated in the AU-011-301 Phase 3 trial. There are no required interventions or use of AU-011 (bel-sar) in this long-term follow-up study

Key Dates

First listed
Jan 14, 2026
Start date
Mar 27, 2026
Status verified
Aug 2026
Primary completion
Aug 15, 2033
Completion
Aug 15, 2033

Study Design

Enrollment
100 participants (estimated)

Primary Outcome Measure

Incidence of adverse events (AEs)/serious AEs. [ Time Frame: 5 years ]

Locations (10)

FacilityCityStateZIPSite coordinators
Retinal Consultants Medical Group, Inc.SacramentoCalifornia95825-
W.K. Kellogg Eye Center - University of MichiganAnn ArborMichigan48105-
Mayo ClinicRochesterMinnesota55905-
Retina Consultants of OklahomaOklahoma CityOklahoma73112-
Retina Consultants of CarolinaGreenvilleSouth Carolina29605-
Tennessee Retina, PCNashvilleTennessee37421-
Austin Retina Associates Ophthalmology/RetinaAustinTexas78705-
Retina Center of TexasSouthlakeTexas76092-
Retina Associates of UtahSalt Lake CityUtah84107-
University of Wisconsin MadisonMadisonWisconsin53705-

Find similar trials in Sacramento, CA